DE60021760D1 - Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem - Google Patents

Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem

Info

Publication number
DE60021760D1
DE60021760D1 DE60021760T DE60021760T DE60021760D1 DE 60021760 D1 DE60021760 D1 DE 60021760D1 DE 60021760 T DE60021760 T DE 60021760T DE 60021760 T DE60021760 T DE 60021760T DE 60021760 D1 DE60021760 D1 DE 60021760D1
Authority
DE
Germany
Prior art keywords
central nervous
nervous system
lymphic
administration
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60021760T
Other languages
English (en)
Other versions
DE60021760T2 (de
Inventor
H Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE60021760D1 publication Critical patent/DE60021760D1/de
Application granted granted Critical
Publication of DE60021760T2 publication Critical patent/DE60021760T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
DE60021760T 1999-12-09 2000-12-08 Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem Expired - Fee Related DE60021760T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20070899P 1999-12-09 1999-12-09
US200708P 1999-12-09
PCT/US2000/033220 WO2001041782A2 (en) 1999-12-09 2000-12-08 Method for administering a cytokine to the central nervous system and the lymphatic system

Publications (2)

Publication Number Publication Date
DE60021760D1 true DE60021760D1 (de) 2005-09-08
DE60021760T2 DE60021760T2 (de) 2006-06-08

Family

ID=22742853

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021760T Expired - Fee Related DE60021760T2 (de) 1999-12-09 2000-12-08 Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem

Country Status (10)

Country Link
US (3) US20010043915A1 (de)
EP (1) EP1237567B1 (de)
JP (1) JP2003516360A (de)
AT (1) ATE300952T1 (de)
AU (1) AU783208B2 (de)
CA (1) CA2393688A1 (de)
DE (1) DE60021760T2 (de)
IL (1) IL150109A0 (de)
NO (1) NO20022731L (de)
WO (1) WO2001041782A2 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
US6589591B1 (en) * 2001-07-10 2003-07-08 Baylor College Of Medicine Method for treating medical devices using glycerol and an antimicrobial agent
WO2003057274A2 (en) * 2001-12-28 2003-07-17 Genzyme Corporation Bioresorbable foam packing device and use thereof
US7674453B2 (en) * 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
WO2003072056A2 (en) * 2002-02-25 2003-09-04 Chiron Corporation Intranasal administration of mc4-r agonists
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
MXPA05009986A (es) * 2003-03-19 2005-11-04 Ares Trading Sa Tratamiento de la enfermedad de alzheimer.
FR2864901B1 (fr) * 2004-01-09 2007-10-05 Philippe Perovitch Composition pour le traitement au contact des hyposialies, incluant de la pilocarpine et a effets multiples
WO2005071101A1 (en) * 2004-01-23 2005-08-04 University Hospital Of Basel Treatment of hepatitis c infection by increasing stat1 methylation
CN1984674A (zh) * 2004-06-07 2007-06-20 纳斯泰克制药公司 不含蛋白质或多肽类稳定剂的干扰素β鼻内制剂
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7776312B2 (en) * 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9114069B2 (en) * 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US8642564B2 (en) * 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20060251619A1 (en) * 2005-05-04 2006-11-09 Gilles Borrelly Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
EP2056800B1 (de) 2005-08-26 2015-12-09 The Board Of Trustees Of The Leland Stanford Junior University Therapieverfahren zur arzneiabgabe gegen trigeminale schmerzen
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
EP1915986A1 (de) * 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Wachstumsfaktorhaltige Lipidformulierungen
US9808509B2 (en) * 2007-06-08 2017-11-07 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
US8221358B2 (en) * 2007-11-20 2012-07-17 Warsaw Orthopedic, Inc. Devices and methods for delivering drug depots to a site beneath the skin
CA2756690C (en) * 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2853269B1 (de) 2008-05-19 2019-05-01 Advaxis, Inc. Doppeltes Freisetzungssystem für heterologe Antigene umfassend einen rekombinanten Listeria - Stamm, attenuiert durch Mutation von dal / dat und Deletion von ActA, umfassend ein Nukleinsäuremolekül, das ein Listeriolysin O - Prostata - spezifisches Antigen - Fusionsprotein codiert
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2310030A4 (de) 2008-06-13 2013-08-14 Wisconsin Alumni Res Found Neue antivirale peptide gegen das influenzavirus
US9198965B2 (en) 2008-06-13 2015-12-01 Wisconsin Alumni Research Foundation Peptide adjuvant for influenza vaccination
US20100106132A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising superior and inferior covers
US9352137B2 (en) * 2008-10-29 2016-05-31 Warsaw Orthopedic, Inc. Drug cartridge for delivering a drug depot comprising a bulking agent and/or cover
US20100106136A1 (en) * 2008-10-29 2010-04-29 Warsaw Orthopedic, Inc. Drug delivery device with sliding cartridge
WO2010068564A1 (en) * 2008-12-11 2010-06-17 Merck Sharp & Dohme Corp. Method for treating alzheimer's disease and related conditions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
ES2784189T3 (es) 2009-03-27 2020-09-23 Academia Sinica Métodos y composiciones para la inmunización contra virus
WO2011011725A2 (en) 2009-07-24 2011-01-27 Schultz-Cherry Stacey L Use of toxoplasma and derived compositions to prevent or treat microbial infections
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
US9468662B2 (en) 2010-07-12 2016-10-18 Orphit Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases
FR2962335B1 (fr) * 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
RU2612506C2 (ru) 2011-03-03 2017-03-09 Импел Ньюрофарма Инк. Устройство для назальной доставки лекарственных средств
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
JP6645735B2 (ja) 2011-05-09 2020-02-14 インペル ニューロファーマ インコーポレイテッド 鼻薬送達用ノズル
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
EP2720699B1 (de) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Verabreichung von benzodiazepin
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
EP2822600A4 (de) 2012-03-09 2016-04-06 Univ Northeastern Verfahren zur abgabe von nucleinsäurenanopartikeln an das zentrale nervensystem zur behandlung von erkrankungen des zentralen nervensystems
SG11201405605VA (en) 2012-03-12 2014-10-30 Advaxis Inc SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT
US9033912B2 (en) 2012-03-28 2015-05-19 Warsaw Orthopedic, Inc. Drug delivery system
US20130280297A1 (en) 2012-04-11 2013-10-24 Lori Neal Use of toxoplasma gene products to prevent or treat microbial infections
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
US10537692B2 (en) 2013-04-28 2020-01-21 Impel Neuropharma, Inc. Medical unit dose container
CA2912678C (en) 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US9901684B2 (en) 2013-10-17 2018-02-27 Warsaw Orthopedic, Inc. Drug delivery device with retaining member
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
WO2015179415A1 (en) 2014-05-19 2015-11-26 Novartis Ag Methods of treating anorexia
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
USD809652S1 (en) 2014-07-25 2018-02-06 Warsaw Orthopedic, Inc. Drug delivery device
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
DK3242676T3 (en) 2015-01-07 2023-11-06 TONIX Pharmaceuticals Holding Corp Magnesium-containing oxytocin formulations and methods of use
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
KR20230125339A (ko) 2016-04-15 2023-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
US10549081B2 (en) 2016-06-23 2020-02-04 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
CN106620656A (zh) * 2017-03-03 2017-05-10 上海唯科生物制药有限公司 一种肿瘤坏死因子舌下给药制剂及其制备方法
WO2019060115A1 (en) 2017-09-19 2019-03-28 Advaxis, Inc. COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
AU2018335752A1 (en) 2017-09-22 2020-03-12 Christian HINDERER Gene therapy for treating Mucopolysaccharidosis type ii
WO2019241579A1 (en) 2018-06-13 2019-12-19 Wisconsin Alumni Research Foundation Toxoplasma gondii vaccine
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
NZ777687A (en) 2019-01-03 2023-12-22 Impel Pharmaceuticals Inc Nasal drug delivery device
EP4319803A1 (de) 2021-04-08 2024-02-14 Vaxthera SAS Coronavirus-impfstoff, der ein mosaikprotein enthält
WO2023069126A1 (en) 2021-10-19 2023-04-27 Odyssey Health, Inc. Breath-powered nasal devices for treatment of traumatic brain injury (tbi), including concussion, and methods and methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4462985A (en) 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4497795A (en) 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4820515A (en) 1982-12-13 1989-04-11 Texas A&M University System Method of using interferon in low dosage to regulate appetite and efficiency of food utilization
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
SU1139444A1 (ru) 1982-12-15 1985-02-15 Iretskij Andrej N Способ введени нейротропных и гормональных препаратов
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
GB8918264D0 (en) * 1989-08-10 1989-09-20 Furnell David Rotary display unit
CA2070823C (en) 1989-12-05 1999-01-12 William H. Ii Frey Neurologic agents for nasal administration to the brain
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5215741A (en) 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
PT647137E (pt) * 1992-06-22 2008-11-24 Univ California Antagonistas dos receptores da glicina e a sua utilização
JPH0741428A (ja) 1993-07-30 1995-02-10 Teijin Ltd ペプチド、蛋白質性薬物経鼻・経肺製剤
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5675942A (en) * 1995-08-28 1997-10-14 Crawford; Van Wall panel alignment device and spacer
CN1151841C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备刺激防御机制或免疫反应的药物中的应用
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
JP2002531490A (ja) * 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
EP1031347B1 (de) 1999-01-27 2002-04-17 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern

Also Published As

Publication number Publication date
US20060159626A1 (en) 2006-07-20
AU2069801A (en) 2001-06-18
AU783208B2 (en) 2005-10-06
US20010043915A1 (en) 2001-11-22
ATE300952T1 (de) 2005-08-15
WO2001041782A3 (en) 2002-01-17
IL150109A0 (en) 2002-12-01
EP1237567A2 (de) 2002-09-11
EP1237567B1 (de) 2005-08-03
US20020141971A1 (en) 2002-10-03
US6991785B2 (en) 2006-01-31
JP2003516360A (ja) 2003-05-13
NO20022731L (no) 2002-08-08
NO20022731D0 (no) 2002-06-07
DE60021760T2 (de) 2006-06-08
CA2393688A1 (en) 2001-06-14
WO2001041782A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
DE60021760D1 (de) Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
WO2005000215A3 (en) Methods for treating pain
CY1107995T1 (el) ΑΝΑΣΤΟΛΗ ΔΡΑΣΤΙΚΟΤΗΤΑΣ p38 ΚΙΝΑΣΗΣ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ΑΡΥΛ ΚΑΙ ΕΤEPΟΑΡΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΤEPΟΚΥΚΛΙΚΕΣ ΟΥΡΙΕΣ
CA2236591A1 (en) Continuous low-dose cytokine infusion therapy
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
JP2003516360A5 (de)
DE69928563D1 (de) Verabreichung von neurotropischen wirkstoffen in das zentrale nervensystem
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
AU2173400A (en) Method for administering agents to the central nervous system
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
RU98115594A (ru) Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
ATE65403T1 (de) Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
ZA865735B (en) Pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
TR199900527T2 (xx) N�rolojik bozukluklar�n tedavisi i�in benzopiranollerin kullan�m�.
DE60235955D1 (de) Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
DE69727222D1 (de) Zusammensetzung und system zur iontophoretischen transdermalen abgabe von medikamenten
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
WO1996034887B1 (en) Antisense peptides
DE60023944D1 (de) Replikationsunfähige herpesvirus-vektoren
Gutmann et al. Origin of intramuscular nerve action potential.
SU1187830A1 (ru) Способ лечени вирусного гепатита у детей
Seki et al. Induction of eosinophil chemotactic factor production from human peripheral blood mononuclear cells by solubilized BALL-1, a B cell lymphoma line
IL163207A (en) Tnf and ifn in neurological diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee